Impaired endothelial function irrespective of systemic inflammation or atherosclerosis in mastocytosis

Öztop, Nida; Özer, Pelin Karaca; Demir, Semra; Beyaz, Şengül; Tiryaki, Tarık Onur; Ozkan, Gulkan; Aydoğan, Mehmet; Buğra, Melike; Çolakoğlu, Bahaüddin; Büyüköztürk, Suna; Nalçacı, Meliha; Yavuz, Akif Selim; Gelincik, Aslı

doi:10.1016/j.anai.2021.03.020

Cited by 4 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have reported that ESM1 is expressed in multiple tissues, including the kidney, liver, thyroid gland, skin, and gastrointestinal tract [14][15][16]. Moreover, aberrant ESM1 expression is associated with multiple diseases, including inflammation [17], vascular disorders [18], and cancer [19].ESM1 is upregulated in a broad spectrum of cancers, often correlated with a poor prognosis [19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Endothelial cell-specific molecule 1 drives cervical cancer progression

et al. 2022

View full text Add to dashboard Cite

The expression, biological functions and underlying molecular mechanisms of endothelial cell-specific molecule 1 (ESM1) in human cervical cancer remain unclear. Bioinformatics analysis revealed that ESM1 expression was significantly elevated in human cervical cancer tissues, correlating with patients’ poor prognosis. Moreover, ESM1 mRNA and protein upregulation was detected in local cervical cancer tissues and various cervical cancer cells. In established and primary cervical cancer cells, ESM1 shRNA or CRISPR/Cas9-induced ESM1 KO hindered cell proliferation, cell cycle progression, in vitro cell migration and invasion, and induced significant apoptosis. Whereas ESM1 overexpression by a lentiviral construct accelerated proliferation and migration of cervical cancer cells. Further bioinformatics studies and RNA sequencing data discovered that ESM1-assocaited differentially expressed genes (DEGs) were enriched in PI3K-Akt and epithelial-mesenchymal transition (EMT) cascades. Indeed, PI3K-Akt cascade and expression of EMT-promoting proteins were decreased after ESM1 silencing in cervical cancer cells, but increased following ESM1 overexpression. Further studies demonstrated that SYT13 (synaptotagmin 13) could be a primary target gene of ESM1. SYT13 silencing potently inhibited ESM1-overexpression-induced PI3K-Akt cascade activation and cervical cancer cell migration/invasion. In vivo, ESM1 knockout hindered SiHa cervical cancer xenograft growth in mice. In ESM1-knockout xenografts tissues, PI3K-Akt inhibition, EMT-promoting proteins downregulation and apoptosis activation were detected. In conclusion, overexpressed ESM1 is important for cervical cancer growth in vitro and in vivo, possibly by promoting PI3K-Akt activation and EMT progression. ESM1 represents as a promising diagnostic marker and potential therapeutic target of cervical cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Endothelial cell-specific molecule 1 drives cervical cancer progression

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These findings have been linked to disease severity. 63 Other neurological conditions have been scarcely described in mastocytosis patients in various case reports. These conditions include parkinsonism, 64 chorea, 65 seizures, 66 syncope, 67 hypotensive shock, 68 encephalopathy due to cerebral hypoxia, 69 peripheral neuropathy, [70][71][72][73] neurosensory deafness, 74 meningeal irritation and compressive myelopathy due to BM infiltration, 71 conus medullaris syndrome, 75 intraspinal tumo 76 and hematomas, 77 and myotonic dystrophy.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, endothelial dysfunction has been previously observed in mastocytosis, characterized by reduced flow‐mediated dilatation and elevated serum vascular endothelial growth factor levels, even in the absence of atherosclerosis or systemic inflammation. These findings have been linked to disease severity 63 …”

Section: Discussionmentioning

confidence: 99%

Cognitive, neuropsychiatric and neurological alterations in mastocytosis: A systematic review

Sagües‐Sesé,

García‐Casares,

Álvarez‐Twose

2023

Clinical & Translational All

View full text Add to dashboard Cite

BackgroundMastocytosis manifests with multisystemic symptoms, often involving the nervous system. Numerous cognitive, neuropsychiatric and neurological alterations have been reported in multiple observational studies.MethodsWe performed a qualitative systematic literature review of reported data consulting the electronic databases Medline, Scopus, Web of Science, Cochrane, and BASE until June 2023.ResultsWe selected 24 studies in which the majority showed that a high proportion of mastocytosis patients suffer cognitive, neuropsychiatric and neurological alterations. The most common disorders and estimated ranges of frequency observed in adults were depression (68%–75%), anxiety, high stress or irritability (27%–54%), cognitive impairment (27%–39%, primarily affecting memory skills), and headaches (55%–69%). Attention challenges and learning difficulties were reported in children at a rate of 13%, while neurodevelopmental disorders occurred at rates of 8%–12%. Frequent white abnormalities in mastocytosis patients with concomitant psychocognitive symptoms have been reported although neuroimaging studies have been performed rarely in this population.ConclusionFurther studies with more comprehensive and homogeneous evaluations and neuroimaging and histological analysis should be performed for a better understanding of these manifestations. An earlier detection and proper management of these symptoms could greatly improve the quality of life of these patients.

show abstract